ABCG2 and cancer: They reported promising molecules showing the inhibition of BCRP in lower nanomolar ranges (Figure 1) [24,25,26,27,28,29], thus paving the way for future adaptation and research in the field of quinazoline-based molecules as optimal inhibitors of BCRP for the improvement of MDR-limited cancer therapies.